Press Release

Mar 27, 2025 The presentation will be webcast at 1:30 PM ET on April 10, 2025 POMPANO BEACH, Fla., March 27, 2025 (GLOBE NEWSWIRE) —BioStem Technologies, Inc.(OTC: BSEM), a leading…

Feb 24, 2025 Study comparing BioStem’s proprietary amnion chorion allograft versus the standard of care aims to demonstrate superior outcomes, further validating its clinical efficacy to support market expansion. POMPANO…

POMPANO BEACH, Fla., Jan. 13, 2025 (GLOBE NEWSWIRE) —BioStem Technologies, Inc.(OTC: BSEM) (“BioStem”, “we”, “us”, or “our”), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived…

Study of Vendaje® versus standard of care aims to show superior wound treatment, supporting market expansion POMPANO BEACH, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) —BioStem Technologies, Inc.(OTC: BSEM), a leading…

Presentation to be webcast at 2:30 PM PT on Monday, January 13, 2025 POMPANO BEACH, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE) —BioStem Technologies, Inc.(OTC: BSEM), a leading MedTech company focused…

Nov 25, 2024Company continues to advance its placental-derived product portfolio with the first patent granted in the fenestrated wound care market POMPANO BEACH, Fla., Nov. 25, 2024 (GLOBE NEWSWIRE) — BioStem…

11/13/2024 By Brad Sorensen, CFA OTC:BSEM READ THE FULL BSEM RESEARCH REPORT BioStem Technologies, Inc. (OTC:BSEM) is a leading innovator focused on harnessing the natural properties of perinatal tissue in the…

The pricing announcement from the Center for Medicare Services became effective on October 1, 2024, and allows BioStem to begin marketing initiatives with Venture Medical POMPANO BEACH, Fla., Oct. 29,…

Advanced wound care MedTech company recently reported a record second-quarter with $116.4M in revenue for H1, 2024 POMPANO BEACH, Fla., Aug. 29, 2024 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC:…